Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands

Journal of Chemical Information and Modeling

Volumn 54, Issue 6, 2014, Pages 1747-1757

  Krautscheid, Yvonne ^a   Senning, Carl Johann Åke ^a   Sartori, Simone B ^a   Singewald, Nicolas ^a   Schuster, Daniela ^a   Stuppner, Hermann ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS;

ACTIVITY PROFILE; IN-HOUSE DATABASE; IN-VITRO TESTING; PHARMACOPHORE MODELING; PHARMACOPHORE MODELS; PHYSIOLOGICAL PROCESS; STRUCTURAL INFORMATION; VIRTUAL SCREENING;

LIGANDS;

ARYLBUTYRIC ACID DERIVATIVE; EPRAZINONE; FENBUTRAZATE; HALOPERIDOL; LIGAND; PROPIOPHENONE DERIVATIVE; TACHYKININ RECEPTOR;

ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DATABASE; DRUG DEVELOPMENT; HUMAN; METABOLISM;

DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; HALOPERIDOL; HUMANS; LIGANDS; MODELS, MOLECULAR; PHENYLBUTYRATES; PROPIOPHENONES; RECEPTORS, TACHYKININ;

EID: 84903279760     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci500106z     Document Type: Article

References (65)

1. Pennefather, J. N.; Lecci, A.; Candenas, M. L.; Patak, E.; Pinto, F. M.; Maggi, C. A. Tachykinins and tachykinin receptors: a growing family Life Sci. 2004, 74, 1445-1463
2. Ebner, K.; Sartori, S. B.; Singewald, N. Tachykinin receptors as therapeutic targets in stress-related disorders Curr. Pharm. Des. 2009, 15, 1647-1674
3. Pinto, F. M.; Almeida, T. A.; Hernandez, M.; Devillier, P.; Advenier, C.; Candenas, M. L. mRNA expression of tachykinins and tachykinin receptors in different human tissues Eur. J. Pharmacol. 2004, 494, 233-239
4. de Swert, K. O.; Joos, G. F. Extending the understanding of sensory neuropeptides Eur. J. Pharmacol. 2006, 533, 171-181
5. Joos, G. F.; Germonpre, P. R.; Pauwels, R. A. Neural mechanisms in asthma Clin. Exp. Allergy 2000, 30, 60-65
6. Hill, R. NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol. Sci. 2000, 21, 244-246
7. Sanofi-Aventis Form 20-F, Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 for the fiscal year ended December 31, 2009; Sanofi-Aventis: Bridgewater, NJ, 2007; p 314.
8. Griebel, G.; Beeské, S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol. Ther. 2012, 133, 116-123
9. Leffler, A.; Ahlstedt, I.; Engberg, S.; Svensson, A.; Billger, M.; Öberg, L.; Bjursell, M. K.; Lindström, E.; Mentzer, B. v. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3 Biochem. Pharmacol. 2009, 77, 1522-1530
10. Bissantz, C.; Bohnert, C.; Hoffmann, T.; Marcuz, A.; Schnider, P.; Malherbe, P. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK 1/NK 3 antagonists J. Med. Chem. 2012, 55, 5061-5076
11. Zakko, S.; Barton, G.; Weber, E.; Dunger-Baldauf, C.; Rühl, A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome Aliment. Pharmacol. Ther. 2011, 33, 1311-1321
12. Gether, U.; Johansen, T. E.; Snider, R. M.; Lowe, J. A.; Nakanishi, S.; Schwartz, T. W. Different binding epitopes on the NK1 receptor for substance P and a non-peptide antagonist Nature 1993, 362, 345-348
13. Fong, T. M.; Yu, H.; Cascieri, M. A.; Underwood, D.; Swain, C. Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists J. Biol. Chem. 1994, 269, 14957-14961
14. Choe, H.-W.; Park, J. H.; Kim, Y. J.; Ernst, O. P. Transmembrane signaling by GPCRs: Insight from rhodopsin and opsin structures Neuropharmacology 2011, 60, 52-57
15. Chandrashekaran, I. R.; Rao, G. S.; Cowsik, S. M. Molecular modeling of the peptide agonist-binding site in a neurokinin-2 receptor J. Chem. Inf. Model. 2009, 49, 1734-1740
16. Ganjiwale, A. D.; Rao, G. S.; Cowsik, S. M. Molecular modeling of neurokinin B and tachykinin NK 3 receptor complex J. Chem. Inf. Model. 2011, 51, 2932-2938
17. Poulsen, A.; Liljefors, T.; Gundertofte, K.; Bjørnholm, B. A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes J. Comput.-Aided Mol. Des. 2002, 16, 273-286
18. Poulsen, A.; Bjørnholm, B.; Gundertofte, K.; Pogozheva, I. D.; Liljefors, T. Pharmacophore and receptor models for neurokinin receptors J. Comput.-Aided Mol. Des. 2003, 17, 765-783
19. Di Fabio, R.; Alvaro, G.; Braggio, S.; Carletti, R.; Gerrard, P. A.; Griffante, C.; Marchioro, C.; Pozzan, A.; Melotto, S.; Poffe, A.; Piccoli, L.; Ratti, E.; Tranquillini, E.; Trower, M.; Spada, S.; Corsi, M. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate Bioorg. Med. Chem. Lett. 2013, 21, 6264-6273
20. OMEGA, version 2.3.3; OpenEye Scientific Software, I.: Santa Fe, NM, 2009,-, 2013.
21. Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584
22. Hawkins, P. C. D.; Nicholls, A. Conformer generation with OMEGA: Learning from the data set and the analysis of failures J. Chem. Inf. Model. 2012, 52, 2919-2936
23. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169
24. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 2012, 40, D1100-D1107
25. Discovery Studio 2.5; Accelrys Inc.: San Diego, CA, 2001-2009.
26. Wolber, G.; Dornhofer, A.; Langer, T. Efficient overlay of small molecules using 3-D pharmacophores J. Comput.-Aided Mol. Des. 2006, 20, 773-788
27. LigandScout program tutorial; Inte:Ligand GmbH: Vienna, Austria.
28. Triballeau, N.; Acher, F.; Brabet, I.; Pin, J.-P.; Bertrand, H.-O. Virtual screening workflow development guided by the ″receiver operating characteristic″ curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4 J. Med. Chem. 2005, 48, 2534-2547
29. Fawcett, T., ROC graphs: Notes and practical considerations for data mining researchers. Technol. Rep. 2003, HPL-2003-4.
30. Cerep. http://www.cerep.fr/Cerep/Users/index.asp.
31. Heuillet, E.; Ménager, J.; Fardin, V.; Flamand, O.; Bock, M.; Garret, C.; Crespo, A.; Fallourd, A. M.; Doble, A. Characterization of a human NK 1 tachykinin receptor in the astrocytoma cell line U 373 MG J. Neurochem. 1993, 60, 868-876
32. Aharony, D.; Little, J.; Powell, S.; Hopkins, B.; Bundell, K. R.; McPheat, W. L.; Gordon, R. D.; Hassall, G.; Hockney, R.; Griffin, R. Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system Mol. Pharmacol. 1993, 44, 356-363
33. Anthes, J. C.; Chapman, R. W.; Richsrd, C.; Eckel, S.; Corboz, M.; Hey, J. A.; Fernandez, X.; Greenfeder, S.; McLeod, R.; Sehring, S.; Rizzo, C.; Crawley, Y.; Shih, N. Y.; Piwinski, J.; Reichard, G.; Ting, P.; Carruthers, N.; Cuss, F. M.; Billah, M.; Kreutner, W.; Egan, R. W. SCH 206272: A potent, orally active tachykinin NK(1) NK(2) and NK(3) receptor antagonist Eur. J. Pharmacol. 2002, 450, 191-202
34. Eistetter, H. R.; Mills, A.; Brewster, R.; Alouani, S.; Rambosson, C.; Kawashima, E. Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells Glia 1992, 6, 89-95
35. Schuster, D.; Waltenberger, B.; Kirchmair, J.; Distinto, S.; Markt, P.; Stuppner, H.; Rollinger, J. M.; Wolber, G. Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part I: Model generation, validation and applicability in ethnopharmacology Mol. Inf. 2010, 29, 75-86
36. Hale, J. J.; Mills, S. G.; MaCcoss, M.; Shah, S. K.; Qi, H.; Mathre, D. J.; Cascieri, M. A.; Sadowski, S.; Strader, C. D.; MacIntyre, D. E.; Metzger, J. M. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)- oxy)-3(S)-phenyl-4-((3-oxo-1,2,4- triazol- 5-yl)methyl)morpholine (1): A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist J. Med. Chem. 1996, 39, 1760-1762
37. Lin, P.; Chang, L.; DeVita, R. J.; Young, J. R.; Eid, R.; Tong, X.; Zheng, S.; Ball, R. G.; Tsou, N. N.; Chicchi, G. G.; Kurtz, M. M.; Tsao, K.-L. C.; Wheeldon, A.; Carlson, E. J.; Eng, W.; Burns, H. D.; Hargreavesd, R. J.; Mills, S. G. The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine Bioorg. Med. Chem. Lett. 2007, 17, 5191-5198
38. Emonds-Alt, X.; Advenier, C.; Cognon, C.; Croci, T.; Daoui, S.; Ducoux, J. P.; Landi, M.; Naline, E.; Neliat, G.; Poncelet, M.; Proietto, V.; Van Broeck, D.; Vilain, P.; Soubrié, P.; Le Fur, G.; Maffrand, J. P.; Brelière, J. C. Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist Neuropeptides 1997, 31, 449-458
39. Maynard, G. D.; Bratton, L. D.; Kane, J. M.; Burkholder, T. P.; Santiago, B.; Stewart, K. T.; Kudlacz, E. M.; Shatzer, S. A.; Knippenberg, R. W.; Farrell, A. M.; Logan, D. E. Synthesis and SAR of 4-(1H-benzimidazole-2- carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity Bioorg. Med. Chem. Lett. 1997, 7, 2819-2824
40. Burkholder, P. T.; Kudlacz, E. M.; Tieu-Binh, L.; Knippenberg, R. W.; Shatzer, S. A.; Maynard, G. D.; Webster, M. E.; Horgan, S. W. Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors Bioorg. Med. Chem. Lett. 1996, 6, 951-956
41. Gerspacher, M.; La Vecchia, L.; Mah, R.; Sprecher, A. v.; Anderson, G. P.; Subramanian, N.; Hauser, K.; Bammerlin, H.; Kimmel, S.; Pawelzik, V.; Ryffel, K.; Ball, H. A. Dual neurokinin NK1/NK2 antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3, 5-bis(trifluoromethyl)benzamides and 3-[N′-3,5-bis(trifluoromethyl) benzoyl-N-arylmethyl-N′-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl] propionamides Bioorg. Med. Chem. Lett. 2001, 11, 3081-3084
42. Nishi, T.; Ishibashi, K.; Takemoto, T.; Nakajima, K.; Fukazawa, T.; Iio, Y.; Itoh, K.; Mukaiyama, O.; Yamaguchi, T. Combined tachykinin receptor antagonist: synthesis and stereochemical structure-activity relationships of novel morpholine analogues Bioorg. Med. Chem. Lett. 2000, 10, 1665-1668
43. Elliott, J. M.; Carling, R. W.; Chicchi, G. G.; Crawforth, J.; Hutson, P. H.; Jones, A. B.; Kelly, S.; Marwood, R.; Meneses-Lorente, G.; Mezzogori, E.; Murray, F.; Rigby, M.; Royo, I.; Russell, M. G. N.; Shaw, D.; Sohal, B.; Tsao, K. L.; Williams, B. N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II Bioorg. Med. Chem. Lett. 2006, 16, 5752-5756
44. Harrison, T.; Korsgaard, M. P. G.; Swain, C. J.; Cascieri, M. A.; Sadowski, S.; Seabrook, G. R. High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template Bioorg. Med. Chem. Lett. 1998, 8, 1343-1348
45. Liu, H.; Altenbach, R. J.; Carr, T. L.; Chandran, P.; Hsieh, G. C.; Lewis, L. G. R.; Manelli, A. M.; Milicic, I.; Marsh, K. C.; Miller, T. R.; Strakhova, M. I.; Vortherms, T. A.; Wakefield, B. D.; Wetter, J. M.; Witte, D. G.; Honore, P.; Esbenshade, T. A.; Brioni, J. D.; Cowart, M. D. cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h] quinazolin-2-amine (A-987306), a new histamine H4 R antagonist that blocks pain responses against carrageenan-induced hyperalgesia J. Med. Chem. 2008, 51, 7094-7098
46. Qi, H.; Shah, S. K.; Cascieri, M. A.; Sadowski, S. J.; MaCcoss, M. L-tryptophan urea amides as NK1NK2 dual antagonists Bioorg. Med. Chem. Lett. 1998, 8, 2259-2262
47. Mah, R.; Gerspachera, M.; Sprecher, A. v.; Stutz, S.; Tschinke, V.; Anderson, G. P.; Bertrand, C.; Subramanian, N.; Ball, H. A. Biphenyl derivatives as novel dual NK1/NK2-receptor antagonists Bioorg. Med. Chem. Lett. 2002, 12, 2065-2068
48. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
49. Ofner, S.; Hauser, K.; Schilling, W.; Vassout, A.; Veenstra, S. J. SAR OF 2-benzyl-4-aminopiperidines: CGP 49823, an orally and centrally active non-peptide NK1 antagonist Bioorg. Med. Chem. Lett. 1996, 1623-1628
50. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Pritchard, M. C.; Raphy, J.; Suman-Chauhan, N. The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists Bioorg. Med. Chem. Lett. 1995, 5, 1773-1777
51. Kordik, C. P.; Luo, C.; Gutherman, M.; Vaidya, A. H.; Rosenthal, D. I.; Crooke, J. J.; McKenney, S. L.; Plata-Salaman, C. R.; Reitz, A. B. Diarylacetylene piperidinyl amides as novel anxiolytics Bioorg. Med. Chem. Lett. 2006, 16, 3065-3067
52. Gilligan, P. J.; Clarke, T.; He, L.; Lelas, S.; Li, Y.-W.; Heman, K.; Fitzgerald, L.; Miller, K.; Zhang, G.; Marshall, A.; Krause, C.; McElroy, J. F.; Ward, K.; Zeller, K.; Wong, H.; Bai, S.; Saye, J.; Grossman, S.; Zaczek, R.; Arneric, S. P.; Hartig, P.; Robertson, D.; Trainor, G. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5- a ]-1,3,5-triazines: Potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF 1) antagonists J. Med. Chem. 2009, 52, 3084-3092
53. Horwell, D. C.; William, H.; Ratcliffe, G.; Willems, H. The design of dipeptide helical mimetics: The synthesis and biological activity of trisubstituted indanes Bioorg. Med. Chem. Lett. 1994, 24, 2825-2830
54. Horwell, D. C.; Lennon, I. C.; Roberts, E. Alternative strategies towards the identification of chemical lead compounds by rational design Bioorg. Med. Chem. Lett. 1994, 4, 525-530
55. Ali, M. A.; Bhogal, N.; Fishwick, C. W. G.; Findlay, J. B. C. Spatial requirements of the antagonist binding site of the NK2 receptor Bioorg. Med. Chem. Lett. 2001, 11, 819-822
56. Debenham, S. D.; Chan, A.; WaiYu Lau, F.; Liu, W.; Wood, H. B.; Lemme, K.; Colwell, L.; Habulihaz, B.; Akiyama, T. E.; Einstein, M.; Doebber, T. W.; Sharma, N.; Wang, C. F.; Wu, M.; Berger, J. P.; Meinke, P. T. Highly functionalized 7-azaindoles as selective PPARc modulators Bioorg. Med. Chem. Lett. 2008, 18, 4798-4801
57. Horwell, D. C.; Naylor, D.; Willems, H. M. G. 2,3-Substituted 2-azanorbornanes as polar β-turn mimetics Bioorg. Med. Chem. Lett. 1997, 7, 31-36
58. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Hughes, J.; McKnight, A. T.; Lewthwaite, R. A.; Pritchard, M. C.; Raphy, J.; Meecham, K.; Ratcliffe, G. S.; Suman-Chauhan, N.; Woodruff, G. N. Use of a dipeptide chemical library in the development of non-peptide tachykinin NK 3 receptor selective antagonists J. Med. Chem. 1996, 39, 1664-1675
59. Horwell, D. C.; Howson, W.; Naylor, D.; Willems, H. M. G. The design of polar b-turn dipeptide mimetics Bioorg. Med. Chem. Lett. 1995, 5, 1445-1450
60. Hanessian, S.; Babonneau, V.; Boyer, N.; La Mannoury Cour, C.; Millan, M. J.; Nanteuil, G. d. Design and synthesis of potential dual NK1/NK3 receptor antagonists Bioorg. Med. Chem. Lett. 2014, 24, 510-514
61. McKeage, K.; Simpson, D.; Wagstaff, A. J. Intravenous droperidol: A review of its use in the management of postoperative nausea and vomiting Drugs 2006, 66, 2123-2147
62. Herpfer, I.; Lieb, K. Substance P receptor antagonists in psychiatry: Rationale for development and therapeutic potential CNS Drugs 2005, 19, 275-293
63. Sokoloff, P. G. B.; Martres, M.-P.; Bouthenet, M.-L.; Schwartz, J.-C. Molecular cloning and characterization of a novel doapmine receptor (D3) as atarget for neuroleptics Nature 1990, 347, 147-151
64. Ramnarine, S. I.; Hirayama, Y.; Barnes, P. J.; Rogers, D. F. 'Sensory-efferent' neural control of mucus secretion: Characterization using tachykinin receptor antagonists in ferret trachea in vitro Br. J. Pharmacol. 1994, 113, 1183-1190
65. Severini, C.; Improta, G.; Falconieri-Erspamer, G.; Salvadori, S.; Erspamer, V. The tachykinin peptide family Pharmacol. Rev. 2002, 54, 285-322